“Years from now, when we tell the Provention Bio story, it won’t just be about financial success, it will be about the impact we have on the patient.”

Andrew Drechsler, Chief Financial Officer, Provention Bio

therapeutic strategy

Pipeline

We have built a carefully selected portfolio of therapeutic candidates that target the interception of autoimmunity to prevent prevalent, chronic, debilitating and life-threatening immune-mediated diseases. Our pipeline spans all stages of development, including a pre-commercial stage therapy for the delay or prevention of the diagnosis of type 1 diabetes (T1D) in individuals at-risk of developing clinical disease.

To learn more about Provention Bio’s clinical trials, please click here.

Focus Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Regulatory

Type 1 Diabetes (T1D) Autoimmunity

At Risk


Newly Diagnosed


Prevention



B-Cell Autoimmunity Checkpoint

SLE


Prevention of immunogenicity


GI Autoimmunity

Celiac Disease


Program Partner

amgen